Opioid-induced constipation

Challenges and therapeutic opportunities

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

There has been an alarming increase in the prescription of opiates and opioids for chronic non-cancer pain in the past 15 years. It is estimated that opiate-induced constipation (OIC) is experienced by 40% of these patients, and that constipation and other gastrointestinal symptoms may dissuade patients from using the required analgesic dose to achieve effective pain relief. Opiates have several effects on gastrointestinal functions, and the inhibition of colonic transit and intestinal and colonic secretion results in constipation. Several different pharmacological approaches are being developed to prevent or treat OIC: prolonged release formulations that contain naloxone (a less specific opiate antagonist that is widely distributed) and a new class of peripherally restricted-opiate receptor antagonists, including methylnaltrexone, alvimopan, tapentadol, NKTR-118, and TD-1211. Novel patient response outcomes have been developed to facilitate demonstration of efficacy and safety of drugs in development for OIC.

Original languageEnglish (US)
Pages (from-to)835-842
Number of pages8
JournalAmerican Journal of Gastroenterology
Volume106
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

Opiate Alkaloids
Constipation
Opioid Analgesics
alvimopan
Therapeutics
Intestinal Secretions
Pain
Opioid Receptors
Naloxone
Prescriptions
Analgesics
Pharmacology
Safety

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Opioid-induced constipation : Challenges and therapeutic opportunities. / Camilleri, Michael.

In: American Journal of Gastroenterology, Vol. 106, No. 5, 05.2011, p. 835-842.

Research output: Contribution to journalArticle

@article{8c157f8e79234a909ebd30bb9c419012,
title = "Opioid-induced constipation: Challenges and therapeutic opportunities",
abstract = "There has been an alarming increase in the prescription of opiates and opioids for chronic non-cancer pain in the past 15 years. It is estimated that opiate-induced constipation (OIC) is experienced by 40{\%} of these patients, and that constipation and other gastrointestinal symptoms may dissuade patients from using the required analgesic dose to achieve effective pain relief. Opiates have several effects on gastrointestinal functions, and the inhibition of colonic transit and intestinal and colonic secretion results in constipation. Several different pharmacological approaches are being developed to prevent or treat OIC: prolonged release formulations that contain naloxone (a less specific opiate antagonist that is widely distributed) and a new class of peripherally restricted-opiate receptor antagonists, including methylnaltrexone, alvimopan, tapentadol, NKTR-118, and TD-1211. Novel patient response outcomes have been developed to facilitate demonstration of efficacy and safety of drugs in development for OIC.",
author = "Michael Camilleri",
year = "2011",
month = "5",
doi = "10.1038/ajg.2011.30",
language = "English (US)",
volume = "106",
pages = "835--842",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Opioid-induced constipation

T2 - Challenges and therapeutic opportunities

AU - Camilleri, Michael

PY - 2011/5

Y1 - 2011/5

N2 - There has been an alarming increase in the prescription of opiates and opioids for chronic non-cancer pain in the past 15 years. It is estimated that opiate-induced constipation (OIC) is experienced by 40% of these patients, and that constipation and other gastrointestinal symptoms may dissuade patients from using the required analgesic dose to achieve effective pain relief. Opiates have several effects on gastrointestinal functions, and the inhibition of colonic transit and intestinal and colonic secretion results in constipation. Several different pharmacological approaches are being developed to prevent or treat OIC: prolonged release formulations that contain naloxone (a less specific opiate antagonist that is widely distributed) and a new class of peripherally restricted-opiate receptor antagonists, including methylnaltrexone, alvimopan, tapentadol, NKTR-118, and TD-1211. Novel patient response outcomes have been developed to facilitate demonstration of efficacy and safety of drugs in development for OIC.

AB - There has been an alarming increase in the prescription of opiates and opioids for chronic non-cancer pain in the past 15 years. It is estimated that opiate-induced constipation (OIC) is experienced by 40% of these patients, and that constipation and other gastrointestinal symptoms may dissuade patients from using the required analgesic dose to achieve effective pain relief. Opiates have several effects on gastrointestinal functions, and the inhibition of colonic transit and intestinal and colonic secretion results in constipation. Several different pharmacological approaches are being developed to prevent or treat OIC: prolonged release formulations that contain naloxone (a less specific opiate antagonist that is widely distributed) and a new class of peripherally restricted-opiate receptor antagonists, including methylnaltrexone, alvimopan, tapentadol, NKTR-118, and TD-1211. Novel patient response outcomes have been developed to facilitate demonstration of efficacy and safety of drugs in development for OIC.

UR - http://www.scopus.com/inward/record.url?scp=79955578050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955578050&partnerID=8YFLogxK

U2 - 10.1038/ajg.2011.30

DO - 10.1038/ajg.2011.30

M3 - Article

VL - 106

SP - 835

EP - 842

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 5

ER -